share_log

Johnson & Johnson | 4: Statement of changes in beneficial ownership of securities-Officer Schmid Timothy

強生 | 4：持股變動聲明-高管 Schmid Timothy

SEC announcement ·  02/21 07:00
牛牛AI助理已提取核心訊息
Timothy Schmid, EVP, WW Chair, MedTech at Johnson & Johnson, was involved in a transaction with the company's stock on February 15, 2024. The specific details of the transaction, such as the number of shares traded, the nature of the shares, the transaction price, and the total value of the shares, were not disclosed in the announcement. As a result, the impact of this event on Schmid's holdings in Johnson & Johnson remains unclear.
Timothy Schmid, EVP, WW Chair, MedTech at Johnson & Johnson, was involved in a transaction with the company's stock on February 15, 2024. The specific details of the transaction, such as the number of shares traded, the nature of the shares, the transaction price, and the total value of the shares, were not disclosed in the announcement. As a result, the impact of this event on Schmid's holdings in Johnson & Johnson remains unclear.
強生公司執行副總裁兼醫療技術全球主席蒂莫西·施密德於2024年2月15日參與了與該公司股票的交易。公告中沒有披露交易的具體細節，例如交易的股票數量、股票的性質、交易價格和股票的總價值。因此，該事件對施密德持有的強生公司的影響尚不清楚。
強生公司執行副總裁兼醫療技術全球主席蒂莫西·施密德於2024年2月15日參與了與該公司股票的交易。公告中沒有披露交易的具體細節，例如交易的股票數量、股票的性質、交易價格和股票的總價值。因此，該事件對施密德持有的強生公司的影響尚不清楚。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。